Chari: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Chari et al., Blood, doi:10.1182/blood.2020008150

24 Dec 2020 Source PDF Share Tweet

Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjusted RR 0.67, p = 0.17 (data is in the supplementary material).

Important missing comments or errors? Let us know.

risk of death, 33.1% lower, RR 0.67, p = 0.17, treatment 8 of 29 (27.6%), control 195 of 473 (41.2%), NNT 7.3.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.

Chari et al., 24 Dec 2020, retrospective, multiple countries, peer-reviewed, median age 69.0, 25 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit